In view of the abundant biological and phenotypic evidence, several clinical trials have been performed, aimed to evaluate the efficacy of specific inhibitors of COX-2 (COXIBs) (Fitzgerald and Patrono, 2001) to prevent or delay the onset (or recurrence) of tumors in high-risk patients, including those with prior removal of colon tumors. The gene discussed is PTGS2; the disease is colonic neoplasm.